Abstract No : 1015
Abstract Type : Poster Discussion Session
Indication : Triple Negative Breast Cancer
Intervention : Halaven (eribulin mesylate) + Keytruda (pembrolizumab)
Company : Eisai Inc./Merck
Technology : Monoclonal antibody
Results:
As of data cutoff (July 31, 2019), 167 pts (Stratum 1, n=66; Stratum 2, n=101) were enrolled and treated. No dose-limiting toxicities were observed. The most common treatment-emergent adverse events were fatigue (66%), nausea (57%), peripheral sensory neuropathy (41%), alopecia (40%), and constipation (37%). No deaths were considered treatment related. The overall ORR was 23.4% (95% CI: 17.2–30.5). Efficacy outcomes by PD-L1 status (PD-L1+, n=74; PDL1-, n=75)
Conclusion:
ERI + PEMBRO has activity in pts with mTNBC. There was a trend toward more robust activity for the combination among patients with PD-L1+ tumors compared to PD-L1- tumors in the first-line setting (Stratum 1); whereas, in the later-line setting (Stratum 2) similar survival outcomes were observed among the PD-L1+ and PD-L1- pts. ERI + PEMBRO shows promise for mTNBC with efficacy that appears greater than historical reports of either agent alone.
Commentary:
Result showed encouraging anticancer ctivity in both first line and later lines, with ORR of 25.8% and 21% respectively.
Refer to Triple Negative Breast Cancer Market report for detailed Insights.
